ArriVent BioPharma (NASDAQ:AVBP) Issues Earnings Results

ArriVent BioPharma (NASDAQ:AVBP) issued its earnings results on Wednesday. The company reported ($0.65) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.65), Zacks reports.

ArriVent BioPharma Stock Down 0.4 %

AVBP traded down $0.09 on Thursday, hitting $23.86. The company had a trading volume of 110,115 shares, compared to its average volume of 122,485. ArriVent BioPharma has a 1-year low of $14.35 and a 1-year high of $25.95. The company’s fifty day moving average price is $19.57 and its 200 day moving average price is $19.16.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on AVBP shares. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of ArriVent BioPharma in a research report on Thursday, June 6th. Oppenheimer reissued an “outperform” rating and issued a $35.00 price target on shares of ArriVent BioPharma in a research note on Thursday. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $30.40.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.